Taken together, these results indicate a combination therapy involving the clinical drug lapatinib or ERBB3 inhibitors, and the natural compound fucoidan may be a novel, safer treatment option for melanoma patients characterized by increased ERBB activity. Here, ERBB3 is linked to melanoma.